Life Sciences & Biotechnology
Title : | Elucidation of Hsp90 Inhibition in Combination with Repurposed Drug Metformin as a Therapeutic Strategy Against Lung Cancer |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Snober Shabnam Mir, Integral University, Uttar Pradesh |
Timeline Start Year : | 2023 |
Timeline End Year : | 2026 |
Contact info : | smir@iul.ac.in |
Equipments : | Image Quant |
Details
Executive Summary : | Lung cancer is a major cause of cancer-related deaths worldwide, with India accounting for 5.5% of total cancer cases. The most common driving mutations for NSCLC are in EGFR and KRAS. However, EGFR mutated NSCLC prevalence is higher in the Asian population than in the United States and Europe. About 30% of NSCLC cases have KRAS mutations in western countries. To advance therapeutic strategies, researchers propose exploring non-cancer drugs for their mutation-specific anticancer potential, either with existing chemotherapeutics or in combination with other novel compounds. Drug repurposing may help identify new targets for anticancer therapies and provide a better understanding of the pathways selectively operative in tumor cells. The working of programmed cell death pathways (apoptosis and autophagy) is most affected in cancer as they interact with multiple signaling cascades that feed into the process of oncogenesis. Understanding the role of heat shock proteins (HSPs) in regulating the crosstalk between apoptosis and autophagy could provide viable anticancer treatment strategies. The study proposes evaluating the effect of a novel Hsp90 inhibitor, gedunin, combined with a repurposed drug, metformin, to elucidate the crosstalk between apoptosis and autophagy in the regulation of cancer survival/growth, metastasis, and drug resistance. Additionally, the study aims to identify the effect of apoptosis inhibition on EGFR and KRAS mutated lung cancer viz-a-viz autophagy. |
Total Budget (INR): | 36,45,400 |
Organizations involved